QDEL · QuidelOrtho Corporation

The thesis

QuidelOrtho's recovery case rests on a signed sale of its point-of-care testing unit that pays down $2.87B of debt. No agreement had been reported by 3 October 2026, so the third-quarter report, estimated for ~4 November 2026, is the next test. Conviction is low because the evidence still points to a process, not a deal.

The narrative is dead as a near-term driver: the Financial Times reported a roughly $1.5B valuation and three named bidders on 27 June 2026, and the shares have since fallen 36.6% over three months to a $10.77 close on 2 October 2026. The 52-week high is $35.38, and the shares sit 69.6% below it.

The prior note retained a $13.75 weekly threshold that the shares breached by 18 September 2026, when the close was $10.62. That level no longer defines the case. The 14-day relative strength index (a gauge of recent buying and selling pressure) has moved from 12.7 on 18 September 2026 to 45.5 on 2 October 2026, so the extreme selling has eased.

Bullish and bearish views on QuidelOrtho Corporation

The bull case on QuidelOrtho Corporation (QDEL), in brief: A sale could cut debt. The bear case: No deal has been announced.

Bull case

• A sale could cut debt. The Financial Times reported on 27 June 2026 that the point-of-care unit was being shopped at about $1.5B, with Advent International, SK Capital Partners and Archimed interested. Total debt was $2.87B at the Q2 report on 6 August 2026, so proceeds of that size would address a large part of it.
• Laboratory sales outside China are growing. The company reported on 6 August 2026 that Q2 laboratory revenue outside China rose 9% year over year. This is the core franchise a buyer of the point-of-care unit would leave behind.
• Margins improved. Q2 adjusted EBITDA was $129M at a 20.5% margin, up 310 basis points year over year (company release, 6 August 2026).
• Analyst targets sit above the price. The consensus target is $14.67 with a Hold rating (StockAnalysis.com, 3 October 2026), and Citigroup's target is $18 with a Neutral rating (Benzinga, 8 July 2026).

Bear case

• No deal has been announced. Management declined to comment on the sale on 6 August 2026, and no agreement or process update was listed after 18 September 2026. Three months of silence after the June report weakens the premise.
• Cash flow guidance is gone. The company withdrew its $100–120M full-year free-cash-flow forecast on 6 August 2026. Cash was $123M against $2.87B of debt, about 4.3 times adjusted EBITDA.
• Earnings guidance was cut. Full-year revenue guidance was reset to $2.52–2.60B and adjusted earnings per share to $0.65–0.90 on 6 August 2026, citing China demand and a softer respiratory season. China revenue fell 23% year over year in Q2.
• Dilution is possible. An automatic registration statement (Form S-3ASR) was filed on 17 July 2026, which lets the company sell shares quickly.
• Analysts are cautious. JPMorgan rates the shares Underweight with a $12 target (Benzinga, 1 July 2026), and the consensus rating is Hold.

Price setup

The adjusted close on 2 October 2026 was $10.77, against a 52-week range of $9.92 to $35.38. The shares trade close to the 52-week low and far below any rising moving average, so there is no stretched gap above trend.

Crowding evidence is thin. The report date is outside the next 30 days, no heavy retail attention is visible in recent headlines, and the automatic registration statement is the only issuance mechanism on file. Single-session moves above 20% have occurred in both directions in 2026, so price can change sharply on a deal headline.

Catalysts, next 30 days

• ~20 October 2026, est. A press release naming the Q3 date. The 6 August 2026 Q2 date was announced on 24 July 2026, and the estimate follows that gap.
• Unscheduled. A definitive agreement for the point-of-care unit, or an announcement that the process has ended.
• ~4 November 2026, est. Q3 2026 results, just after the 30-day window. The date is unconfirmed.

What would change the view

The case breaks if the company ends the point-of-care sale process, signs a deal with proceeds too small to reduce debt, or cuts full-year revenue guidance below $2.52B. A daily close below $9.92, the 52-week low, would also end it.

The case improves with a signed agreement stating cash proceeds available for debt repayment, or a reinstated free-cash-flow forecast at the Q3 report. A final Chinese pricing guideline that shows the 23% revenue decline was a one-time reset would also help.

What it trades with

QuidelOrtho trades mainly on company-specific events: the sale process, the balance sheet and its guidance. Its Q2 results tied it to respiratory-season testing volumes and to China diagnostics pricing. The sale story has driven the share price on days when it moved the broader diagnostics group.